The Bioinformatics Application in Detecting Germline and Somatic Variants towards Breast Cancer using Next Generation Sequencing

Rizka Retnomawarti, Sonar Soni Panigoro, Rafika Indah Paramita
https://doi.org/10.35877/454RI.asci1608

Abstract

Breast cancer is the type of cancer with the most and the highest cases causing mortality in Indonesia, so an effective   treatment is required to reduce the incidence and mortality rate due to cancer breasts. Most breast cancer patients are   diagnosed at an advanced stage so the treatment used are limited and the risk of death becomes higher. Along with the development of human genome sequencing technology, the genetic examination of breast cancer is considered as an examination that can be used for early prevention and treatment management personally. Based on the target variants detected, the genetic examination of breast cancer can be divided into two, namely the examination of germline variants and somatic variants. Germline variant examination is intended to predict the risk of breast cancer which can be used as an early preventive measure, while somatic variant examination is intended for cancer diagnosis    and management therapy. NGS technology is able to detect both types of variants in a number of genes associated with breast cancer in several samples effectively and quickly. However, the data generated from NGS technology is very large and complex, so the role of bioinformatics is required in analyzing and interpreting data. By utilizing bioinformatics pipelines and tools, analysis of germline variants and somatic variants in breast cancer can be carried out accurately so that the results of genetic examinations can be used as a step to treat breast cancer. 

Keywords

Downloads

Download data is not yet available.

References (31)

  1. Bai, H., Yu, J., Jia, S., Liu, X., Liang, X., & Li, H. (2021). Prognostic value of the tp53 mutation location in metastatic breast cancer as detected by next-generation sequencing. Cancer Management and Research, 13, 3303–3316. https://doi.org/10.2147/CMAR.S298729
  2. Behjati, S., & Tarpey, P. S. (2013). What is next generation sequencing? Archives of Disease in Childhood: Education and Practice Edition, 98(6), 236–238. https://doi.org/10.1136/archdischild-2013-304340
  3. Broad Institute. (2020). Somatic short variant discovery (SNVs + Indels). Broad Institute.
  4. Campbell, P. J., & Martincorena, I. (2015). Somatic mutation in cancer and normal cells. Science, 349(6255), 1483–1488.
  5. Chatrath, A., Ratan, A., & Dutta, A. (2021). Germline Variants That Affect Tumor Progression. Trends in Genetics, 37(5), 433–443. https://doi.org/10.1016/j.tig.2020.10.005
  6. Desai, N. V., Yadav, S., Batalini, F., Couch, F. J., & Tung, N. M. (2021). Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk-based testing of those older than 60 years. Cancer, 127(6), 828–833. https://doi.org/10.1002/cncr.33305
  7. Ginsburg, O., Yip, C. H., Brooks, A., Cabanes, A., Caleffi, M., Yataco, J. A. D., Gyawali, B., McCormack, V., de Anderson, M. M. L., Mehrotra, R., Mohar, A., Murillo, R., Pace, L. E., Paskett, E. D., Romanoff, A., Rositch, A. F., Scheel, J. R., Schneidman, M., Unger-Saldaña, K., … Anderson, B. O. (2020). Breast Cancer Early Detection: A Phased Approach to Implementation. Cancer, 126(S10). https://doi.org/10.1002/cncr.32887
  8. Huang, Y., & Davidson, N. E. (2006). Breast cancer. Principles of Molecular Medicine, 728–735. https://doi.org/10.1007/978-1-59259-963-9_74
  9. Ilumina. (2021). Next-Generation Sequencing (NGS) | Explore the technology. Innovative Technologies.
  10. Institute, B. (n.d.). Germline short variant discovery (SNPs + Indels). Germline Short Variant Discovery (SNPs + Indels).

How to Cite

Retnomawarti, R., Panigoro, S. . S., & Paramita, R. I. (2023). The Bioinformatics Application in Detecting Germline and Somatic Variants towards Breast Cancer using Next Generation Sequencing. Journal of Applied Science, Engineering, Technology, and Education, 5(1), 25–34. https://doi.org/10.35877/454RI.asci1608